v3.26.1
Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting [Line Items]      
Total revenue from reportable segments $ 1,618,499 $ 1,526,594 $ 1,321,776
Cost of commissions and other services revenue (312,153) (305,127) (318,798)
Cost of goods sold—pharmacy revenue (730,748) (630,340) (405,004)
Marketing expense (313,687) (319,505) (358,858)
Technical development (38,965) (38,681) (33,524)
Selling, general, and administrative (149,022) (164,442) (141,042)
All Other Adjusted EBITDA 13,336 10,597 14,127
Corporate (104,725) (98,070) (91,863)
Share-based compensation expense (14,862) (18,357) (13,816)
Transaction costs (2,112) (14,617) (13,158)
Depreciation and amortization (17,489) (20,460) (24,998)
Loss on disposal of property, equipment, and software, net   (240) (536)
Impairment of long-lived assets 0 (4,209) 0
Impairment of equity-method investment (1,000) 0 0
Loss on extinguishment of debt (8,659) 0 0
Change in fair value of warrants 55,804 59,525 0
Interest expense, net (44,527) (79,385) (93,551)
INCOME (LOSS) BEFORE INCOME TAX EXPENSE 76,287 48,511 (29,066)
Unallocated corporate expenses 69,300 65,100 61,700
Professional services 19,100 17,200 17,800
Facilities 5,200 5,700 4,200
Severance expenses 1,300 800 2,400
Financing transaction costs 800 13,800 9,100
Operating Segments      
Segment Reporting [Line Items]      
Total revenue from reportable segments 1,606,921 1,516,076 1,292,287
Cost of commissions and other services revenue
Marketing expense
Technical development
Selling, general, and administrative
Adjusted Segment EBITDA 200,521 213,727 194,729
Operating Segments | Senior      
Segment Reporting [Line Items]      
Total revenue from reportable segments 575,947 600,393 655,849
Cost of commissions and other services revenue (202,587) (201,933) (216,348)
Cost of goods sold—pharmacy revenue 0 0 0
Marketing expense (222,977) (234,335) (269,867)
Technical development 0 0 0
Selling, general, and administrative (2,357) (2,454) (2,890)
Adjusted Segment EBITDA 148,026 161,671 166,744
Operating Segments | Healthcare Services      
Segment Reporting [Line Items]      
Total revenue from reportable segments 844,935 742,705 478,508
Cost of commissions and other services revenue (27,306) (25,163) (17,438)
Cost of goods sold—pharmacy revenue (724,907) (625,389) (400,821)
Marketing expense (7,820) (8,038) (6,260)
Technical development (1,356) (2,187) (915)
Selling, general, and administrative (58,063) (56,541) (45,253)
Adjusted Segment EBITDA 25,483 25,387 7,821
Operating Segments | Life      
Segment Reporting [Line Items]      
Total revenue from reportable segments 186,039 172,978 157,930
Cost of commissions and other services revenue (70,250) (65,047) (60,017)
Cost of goods sold—pharmacy revenue 0 0 0
Marketing expense (87,773) (80,269) (76,513)
Technical development 0 0 0
Selling, general, and administrative (1,004) (993) (1,236)
Adjusted Segment EBITDA $ 27,012 $ 26,669 $ 20,164